Viewing Study NCT02306850


Ignite Creation Date: 2025-12-24 @ 4:48 PM
Ignite Modification Date: 2026-01-04 @ 3:30 PM
Study NCT ID: NCT02306850
Status: COMPLETED
Last Update Posted: 2019-06-20
First Post: 2014-12-01
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Sponsor:
Organization: